MiRNA-20b/SUFU/Wnt axis accelerates gastric cancer cell proliferation, migration and EMT.
EMT
SUFU
Wnt/β-catenin
miRNA-20b
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
12
2019
revised:
17
08
2020
accepted:
01
04
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Previous research has found that miRNA-20b is highly expressed in gastric cancer (GC), however, its function and underlying mechanism are not clear. Wnt signaling pathway, implicated in tumorigeneisis, is activated in more than 30% of GC. We would like to characterize the biological behavior of miRNA-20b in terms of modulating Wnt/β-catenin signaling and EMT. We showed that miRNA-20b inhibitors suppressed Topflash/Fopflash dependent luciferase activity and the β-catenin nuclear translocation, resulting in inhibition of Wnt pathway activity and EMT. SUFU, negatively regulating Wnt and Hedgehog signaling pathway, was proved to be targeted by miRNA-20b. Moreover, additional knockdown of SUFU alleviated the inhibitory effect on Wnt pathway activity, EMT, cell proliferation/migration and colony formation caused by miRNA-20b inhibition. In summary, miRNA-20b is an oncogenic miRNA and promoted cell proliferation, migration and EMT in GC partially by activating Wnt pathway via targeting SUFU.
Identifiants
pubmed: 33912703
doi: 10.1016/j.heliyon.2021.e06695
pii: S2405-8440(21)00798-2
pmc: PMC8065298
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e06695Subventions
Organisme : NIMHD NIH HHS
ID : U54 MD007597
Pays : United States
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Dig Dis Sci. 2019 Oct;64(10):2830-2842
pubmed: 30997579
J Biol Chem. 2009 Jan 16;284(3):1612-9
pubmed: 18996844
Cancer Res. 2002 Jun 15;62(12):3503-6
pubmed: 12067995
Cell Biosci. 2014 Oct 14;4(1):62
pubmed: 25364498
Oncol Rep. 2018 Dec;40(6):3323-3334
pubmed: 30542715
Oncotarget. 2015 Nov 3;6(34):35579-88
pubmed: 26417932
Mol Ther Nucleic Acids. 2020 Sep 4;21:315-331
pubmed: 32622332
Int J Oncol. 2009 Feb;34(2):537-42
pubmed: 19148490
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Biosci. 2018 Jan 10;8:2
pubmed: 29344346
Oncol Lett. 2017 Dec;14(6):6895-6900
pubmed: 29163708
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
PLoS One. 2016 Oct 4;11(10):e0164105
pubmed: 27701465
Oncol Lett. 2019 Mar;17(3):2931-2936
pubmed: 30854070
Nat Commun. 2016 Oct 04;7:12885
pubmed: 27698350
Sci Rep. 2014 Aug 15;4:6088
pubmed: 25124853
J Gastroenterol Hepatol. 2009 Apr;24(4):652-7
pubmed: 19175831
Dis Markers. 2015;2015:325176
pubmed: 26612965
Oncotarget. 2015 Nov 17;6(36):38705-18
pubmed: 26462018
Cancer Lett. 2017 Jan 28;385:117-127
pubmed: 27810403
Oncogene. 2007 Jul 12;26(32):4617-26
pubmed: 17237808
Mol Carcinog. 2018 Sep;57(9):1223-1236
pubmed: 29749061
Onco Targets Ther. 2015 Jul 24;8:1871-6
pubmed: 26244024
Hum Immunol. 2014 Apr;75(4):348-53
pubmed: 24468585
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5
pubmed: 18077375
Breast Cancer Res Treat. 2018 Jul;170(2):257-270
pubmed: 29557526
J Biol Chem. 2005 Mar 25;280(12):11740-8
pubmed: 15647282
Immunol Rev. 2013 May;253(1):129-45
pubmed: 23550643
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Oncotarget. 2017 Jun 21;8(33):55489-55510
pubmed: 28903436
Int J Mol Sci. 2020 Jan 29;21(3):
pubmed: 32013265
Cell Oncol (Dordr). 2013 Oct;36(5):421-35
pubmed: 24027019